{"prompt": "['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 7 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', '6', 'Time between visits 2 and 3 may be extended for up to 6 weeks to allow scheduling of the onset of pulmonary', 'rehabilitation, the treatment period will begin on the first day of pulmonary rehabilitation and all visits move accordingly', 'to keep the same visit schedule.', '7', 'Height and weight to be collected at Visit 1 only.', '01-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 8 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', 'TABLE OF CONTENTS', 'TITLE PAGE', '1', 'CLINICAL TRIAL PROTOCOL SYNOPSIS', '2', 'FLOW CHART', '6', 'TABLE OF CONTENTS', '8', 'ABBREVIATIONS', '12', '1.', 'INTRODUCTION', '15', '1.1', 'MEDICAL BACKGROUND', '15', '1.2', 'DRUG PROFILE', '15', '1.3', 'RATIONALE FOR PERFORMING THE TRIAL', '15', '1.4', 'BENEFIT - RISK ASSESSMENT', '16', '2.', 'TRIAL OBJECTIVES AND ENDPOINTS', '17', '2.1', 'MAIN OBJECTIVES, PRIMARY AND SECONDARY ENDPOINTS', '17', '2.1.1', 'Main objectives', '17', '2.1.2', 'Primary endpoint(s)', '17', '2.1.3', 'Secondary endpoint(s)', '17', '3.', 'DESCRIPTION OF DESIGN AND TRIAL POPULATION', '19', '3.1', 'OVERALL TRIAL DESIGN AND PLAN', '19', '3.2', 'DISCUSSION OF TRIAL DESIGN, INCLUDING THE CHOICE OF', 'CONTROL GROUP(S)', '19', '3.3', 'SELECTION OF TRIAL POPULATION', '19', '3.3.1', 'Main diagnosis for trial entry', '20', '3.3.2', 'Inclusion criteria', '20', '3.3.3', 'Exclusion criteria', '21', '3.3.4', 'Withdrawal of patients from therapy or assessments', '21', '3.3.4.1', 'Withdrawal from trial treatment', '22', '3.3.4.2', 'Withdrawal of consent for trial participation', '22', '3.3.4.3', 'Discontinuation of the trial by the sponsor', '22', '4.', 'TREATMENTS', '24', '4.1', 'INVESTIGATIONAL TREATMENTS', '24', '4.1.1', 'Identity of the investigational medicinal products', '24', '4.1.2', 'Selection of doses in the trial', '24', '4.1.3', 'Method of assigning patients to treatment groups', '24', '4.1.4', 'Drug assignment and administration of doses for each patient', '24', '4.1.5', 'Blinding and procedures for unblinding', '25', '4.1.5.1', 'Blinding', '25', '4.1.5.2', 'Unblinding and breaking the code', '25', '4.1.6', 'Packaging, labelling, and re-supply', '25', '01-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 9 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', '4.2', 'OTHER TREATMENTS, EMERGENCY PROCEDURES,', 'RESTRICTIONS', '25', '4.2.1', 'Other treatments and emergency procedures', '25', '4.2.1.1', 'Management of adverse events related to nintedanib', '25', '4.2.1.2', 'Management of other adverse events', '25', '4.2.2', 'Restrictions', '25', '4.2.2.1', 'Restrictions on concomitant treatment', '25', '4.2.2.2', 'Concomitant treatments allowed', '26', '4.2.2.3', 'Restrictions on diet and life style', '26', '4.2.2.4', 'Restrictions regarding women of childbearing potential', '27', '4.3', 'TREATMENT COMPLIANCE', '27', '5.', 'ASSESSMENTS', '28', '5.1', 'ASSESSMENT OF EFFICACY', '28', '5.1.1', 'Endpoints of efficacy', '28', '5.1.1.1', 'Primary endpoint', '28', '5.1.1.2', 'Secondary endpoints', '28', '5.1.2', 'Assessment of efficacy', '29', '5.1.2.1', '6 Minute walk test', '29', '5.1.2.2', 'Change in quality of life', '29', '5.1.2.3', 'Assessment of lung function', '29', '5.1.2.4', 'Daily activity monitoring', '30', '5.1.2.6', 'PROactive tool', '31', '5.2', 'ASSESSMENT OF SAFETY', '31', '5.2.1', 'Physical examination', '31', '5.2.2', 'Vital signs', '31', '5.2.3', 'Safety laboratory parameters', '32', '5.2.4', 'Electrocardiogram', '33', '5.2.5', 'Other safety parameters', '33', '5.2.6', 'Assessment of adverse events', '33', '5.2.6.1', 'Definitions of AEs', '33', '5.2.6.2', 'Adverse event and serious adverse event collection and reporting', '35', '5.2.6.3', 'Reporting to health authorities', '37', '5.3', 'DRUG CONCENTRATION MEASUREMENTS AND', 'PHARMACOKINETICS', '37', '5.3.1', 'Assessment of pharmacokinetics', '37', '5.3.2', 'Methods of sample collection', '37', '5.3.3', 'Analytical determinations', '37', '5.3.4', 'Pharmacokinetic - pharmacodynamic relationship', '37', '5.4', 'ASSESSMENT OF BIOMARKER(S)', '37', '5.5', 'OTHER ASSESSMENTS', '38', '5.6', 'APPROPRIATENESS OF MEASUREMENTS', '38', '6.', 'INVESTIGATIONAL PLAN', '39', '6.1', 'VISIT SCHEDULE', '39', '001-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']\n\n###\n\n", "completion": "END"}